MedTrace Logo

Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

NCT06514313 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2024-07-23

No results posted yet for this study

Summary

Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine

Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.

DRUG

Temozolomide+Irinotecan+Vincristine

Q3W, 4 cycles

Sponsors & Collaborators

  • Yizhuo Zhang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2026-08-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514313 on ClinicalTrials.gov